Biolife Solutions (BLFS) Stock
Storage systems and supplies for cell and gene therapies. Here's the price, business snapshot, and what's worth knowing about Biolife Solutions in August 2026.
BioLife Solutions (BLFS) provides specialised biopreservation media, storage systems and cold-chain logistics tools used by developers and manufacturers of cell and gene therapies. With a market capitalisation of about $1.33bn, the company sits at the intersection of life-science tools and advanced therapeutics supply chains. Investors should note it earns revenue largely from consumables and distribution services, which can support recurring sales, but growth depends on the pace of adoption of cell and gene therapies and on partners’ clinical and commercial progress. There is exposure to regulatory approvals, competitive products, and the capital intensity of scaling biological supply chains. Financial performance can be variable as customers move through development cycles. This note is for educational purposes only and not personalised advice; investors should assess whether a growth-oriented, higher‑risk healthcare stock fits their objectives and consider seeking independent financial advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioLife Solutions' stock, with a target price of $32.22, indicating strong growth potential.
Financial Health
BioLife Solutions is generating solid revenue and cash flow, with a strong profit margin indicating good efficiency.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Cell therapy demand
Rising development of cell and gene therapies can boost recurring consumable sales, though adoption rates and customer progress vary and affect revenue.
Cold‑chain logistics
Reliable temperature‑controlled transport is essential for biologics; operational execution and regulation matter, and lapses can affect customers and revenues.
Early‑stage volatility
The company sits in a growth phase with potential upside, but financial results can be lumpy and sensitive to partner timelines and broader biotech cycles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
